Other similar studies noted reduced neutrophilia with the use of danirixin (a CXCR2 inhibitor) [56,57] and navarixin (MK-7123/SCH 527123) [58] in phase 2 clinical trials in influenza and COPD cases. The gene discussed is CXCR2; the disease is influenza.